Chronic Myeloid Leukemia Coverage from Every Angle

Recent News

Case Report of CML With Primary Blast Crisis and Marrow Fibrosis
Infliximab Therapy With Tyrosine Kinase Inhibition in CML
Comparing Asciminib and Bosutinib in Resistant CML
Does SIRT1 Play a Role in Chronic Myeloid Leukemia Development?
Trial Update on Lower-Dose Dasatinib in Newly Diagnosed CML
Treatment-Free Remission After Dasatinib Discontinuation in CML
Long-Term Update on Treatment-Free Remission After First-Line Nilotinib in CML
EHA24 Congress: Phase IV BYOND Trial of Bosutinib in Resistant CML
EHA24 Congress: Cardiovascular Events and Nilotinib Treatment in CML
EHA24 Congress: Second-Generation TKI in CML After Suboptimal Response to Imatinib
ASCO 2019: BYOND Study Update on Bosutinib in Chronic Phase CML
ASCO 2019: Is Front-Line Flumatinib as Effective as Imatinib in CML?
ASCO 2019: Long-Term Follow-up on Treatment-Free Remission in CML
Use of Tyrosine Kinase Inhibitors During Pregnancy for Women With CML
Novel Strategy to Inhibit Imatinib Resistance With Indirubin
Tyrosine Kinase Inhibitor Discontinuation in CML: Real-World Experience
Role of CCN3 Hypermethylation in CML
Update on Issues in Treating and Monitoring Patients With CML
Sensitivity of Molecular Monitoring in TKI Stopping Trials in CML
Rare Case of Unilateral CML Retinopathy Reported
Monitoring First-Line Treatment of Nilotinib in CML
HOPA 2019: Considering Comorbidities When Selecting a Second-Generation TKI in CML
Medication Adherence and Cost for Patients With CML
Identifying Imatinib-Resistant Mutations in Patients With CML
Psychological Experience of Living With CML: From the Patient Perspective
Imatinib’s Potential Long-Term Effects on Pregnancy and Implantation
Study Finds Novel Compound Reduces Survival of Imatinib-Resistant CML Cells
Translational CML Study of Nilotinib Versus Imatinib: Focus on Adipocyte Toxicity

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.